Global R&D Pipeline
My Favorite
Hot Targets:
c-MET
Back
Total number of drugs
352
Phase II and later clinical stages
9.9%
Involving companies
439
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amivantamab-VMJM/Hyaluronidase | Amivantamab-VMJM/Hyaluronidase | Bispecific antibody Enzyme | Neoplasms Respiratory Diseases | EGFR antagonists Hyaluronic acid modulators c-Met inhibitors | Johnson & Johnson | Janssen Research & Development LLC Janssen Medical Affairs | Phase 3 | Phase 3 | - | - | - | - | - | - | - | - | Amivantamab-VMJM/Hyaluronidase | - | - | detail > | |
| Crizotinib | Crizotinib | Small molecule drug | Neoplasms Immune System Diseases Hemic and Lymphatic Diseases Respiratory Diseases Other Diseases Eye Diseases Skin and Musculoskeletal Diseases Nervous System Diseases Digestive System Disorders Endocrinology and Metabolic Disease Urogenital Diseases | ALK inhibitors EML4-ALK inhibitors MST1R inhibitors ROS1 inhibitors c-Met inhibitors | Pfizer Global Manufacturing China | Huizhi Pharmaceutical (Dalian) Co., Ltd. Pfizer Europe MA EEIG IDEAYA Biosciences, Inc. Pfizer Inc. PF Prism CV | Approved | Approved | United States China European Union Japan Canada Australia Switzerland Iceland South Korea Liechtenstein Norway | 2011-08-26 | 2013-01-22 | Accelerated Approval（United States） Breakthrough Therapy（United States） Orphan Drug（South Korea） Orphan Drug（United States） Priority Review（China） Special Review Project（China） Orphan Drug（Japan） | - | - | - | - | Crizotinib | - | - | detail > | |
| Recombinant plasmid-hepatocyte growth factor(Academy of Military Medical Sciences) | Recombinant plasmid-hepatocyte growth factor(Academy of Military Medical Sciences) | Growth factors | Nervous System Diseases Other Diseases Cardiovascular Diseases | c-Met modulators | Academy of Military Medical Sciences | Wuhan Optical Valley Humanwell Biological Pharmaceutical Co. Jiangsu Yaohai Bio-pharmaceutical Co., Ltd. Chinese People's Liberation Army General Hospital Humanwell Healthcare (Group) Co., Ltd. | NDA/BLA | NDA/BLA | - | - | - | - | - | - | - | - | Recombinant plasmid-hepatocyte growth factor(Academy of Military Medical Sciences) | - | - | detail > | |
| Zanzalintinib | Zanzalintinib | Small molecule drug | Neoplasms Digestive System Disorders Urogenital Diseases Infectious Diseases Other Diseases Endocrinology and Metabolic Disease Skin and Musculoskeletal Diseases Respiratory Diseases | AXL inhibitors MerTK inhibitors VEGFR1 antagonists c-Met inhibitors | Exelixis, Inc. | Exelixis, Inc. Merck Sharp & Dohme LLC | Phase 3 | - | - | - | - | - | - | - | - | - | Zanzalintinib | - | - | detail > | |
| ST-1898 | ST-1898 | Small molecule drug | Neoplasms Endocrinology and Metabolic Disease Skin and Musculoskeletal Diseases Urogenital Diseases Other Diseases | AXL inhibitors PDGFR antagonists RTK inhibitors VEGFR antagonists c-Kit inhibitors c-Met inhibitors | Beijing Saite Mingqiang Pharmaceutical Technology Co., Ltd. | Beijing Saite Mingqiang Pharmaceutical Technology Co., Ltd. | Phase 3 | Phase 3 | - | - | - | - | - | - | - | - | ST-1898 | - | - | detail > | |
| Sitravatinib | Sitravatinib | Small molecule drug | Neoplasms Digestive System Disorders Eye Diseases Skin and Musculoskeletal Diseases Urogenital Diseases Other Diseases Respiratory Diseases | AXL inhibitors RET inhibitors Tie-2 antagonists VEGFR1 antagonists VEGFR2 antagonists VEGFR3 antagonists c-Met inhibitors | Mirati Therapeutics, Inc. | BeOne Medicines Ltd. Mirati Therapeutics, Inc. BeiGene Pharmaceuticals (Guangzhou) Co. Ltd. | Phase 3 | Phase 3 | - | - | - | - | - | - | - | - | Sitravatinib | - | - | detail > | |
| PM-1080 | PM-1080 | Bispecific antibody | Neoplasms Respiratory Diseases Digestive System Disorders | EGFR antagonists c-Met inhibitors | Biotheus, Inc. | Shanghai Hansoh Biomedical Co. Ltd. Jiangsu Hansoh Pharmaceutical Co., Ltd. Changzhou Hansoh Pharmaceutical Co., Ltd. | Phase 3 | Phase 3 | - | - | - | - | - | - | - | - | PM-1080 | - | - | detail > | |
| Telisotuzumab vedotin | Telisotuzumab vedotin | Antibody drug conjugate (ADC) | Neoplasms Respiratory Diseases | Tubulin inhibitors c-Met inhibitors | AbbVie, Inc. | AbbVie, Inc. | Approved | Phase 3 | United States | 2025-05-14 | - | Accelerated Approval（United States） Breakthrough Therapy（China） Breakthrough Therapy（United States） Orphan Drug（United States） | telisotuzumab | Mc-Val-Cit-PABC-PNP | MMAE | 3 - 4 | Telisotuzumab vedotin | IgG1 - kappa | lysyl | detail > | |
| Dalmelitinib | Dalmelitinib | Small molecule drug | Neoplasms Respiratory Diseases | c-Met inhibitors | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 3 | Phase 3 | - | - | - | Special Review Project（China） | - | - | - | - | Dalmelitinib | - | - | detail > | |
| Envonalkib | Envonalkib | Small molecule drug | Neoplasms Respiratory Diseases | ALK inhibitors ROS1 inhibitors c-Met inhibitors | Shouyao Holdings (Beijing) Co. Ltd. | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Approved | Approved | China | 2024-06-11 | 2024-06-11 | Special Review Project（China） | - | - | - | - | Envonalkib | - | - | detail > |
Total 352 data
1
2
3
4
5
6
...
35
36
